Navigation Links
Registry: Do medications which reduce angina
Date:8/30/2011

Although medication which decreases the risk of angina attacks (chest pain caused by blockage of the arteries that supply the heart), are frequently prescribed in patients who have sustained a myocardial infarction, the possible influence of medication on long-term survival is not known, with the exception of beta-blocking agents, which have been shown to decrease mortality in clinical trials performed 30 years ago. Because antianginal drugs also protect the myocardium against ischemia (insufficient oxygen delivery to the heart muscle), there is a possibility that they may improve the prognosis of patients having suffered a heart attack. There are several classes of antianginal medications, which act through different mechanisms and therefore may have different effects on the clinical prognosis of patients.

The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI), is a nationwide survey of patients hospitalised for acute myocardial infarction in France over a one-month period, at the end of 2005. Patients included will be followed for a period of 10 years after the initial heart attack. At three years, fewer than 5% of the patients have been lost to follow-up.

Of a population of 3,670 patients included in the registry, 3,262 survived the initial hospitalisation and had a complete prescription at discharge. Among them, 1266 (39%) received antianginal agents other than beta-blockers. Calcium-channel blockers were prescribed to 16% (dihydropyridines 10.5%, diltiazem 2% or verapamil 3%), nitrates to 19%, molsidomine to 3%, nicorandil to 9% and trimetazidine to 4.5% of patients. In addition, beta-blockers were prescribed to 77% of the patients. Patients who received antianginal agents were older and had more severe infarctions than those who did not receive such medications.

Three-year survival was 77% in patients treated with antianginal agents, compared with 86% in those who were not. After taking into account the initial profile of the patients and the severity of their heart attacks, prescription of antianginal medications was associated with a small (7%), non significant increase in the risk of dying in the 3 years following the heart attack.

When the different antianginal agents were analysed individually, none was associated with either a decreased or an increased risk of dying, except for molsidomine. Prescription of nitrates, the most ancient antianginal medication available, was associated with a trend to increased risk of death (+ 22%) which was not statistically significant; molsidomine was prescribed in a small number of patients (n=111) and was associated with a significant excess of deaths (+ 57%).

There was no evidence of any benefit or harm with respect to long-term mortality with most antianginal agents prescribed in patients having sustained a heart attack. The findings of possible increased hazard associated with use of nitrates, and more importantly of molsidomine, are intriguing and deserve further studies.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-633-473-335
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Excessive Heat Can Harm Medications, Expert Says
2. Pivotal study in Africa finds that HIV medications prevent HIV infection
3. No increase in severe cardiovascular events for children, adolescents taking ADHD medications
4. Researchers report widespread use of medications among pregnant women
5. Evidence Weak to Support Many Medications for Autism: Study
6. Massachusetts General Hospital leading nationwide, comparative study of common bipolar medications
7. Instructions on over-the-counter medications for children are found to be confusing
8. Missed opportunities: Most heart attack patients are not taking preventive medications
9. Medications found to cause long term cognitive impairment of aging brain
10. Psychotropic medications can cause birth defects
11. Publix Pharmacy Now Offers Pill Glide, an Innovative New Way for Children and Adults to Take Vitamins, Supplements and Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... pluripotent stem (iPS) cells and other difficult to transfect cells, announces its launch ... PluriQ™ G9™ Gene Editing System is a complete system for culturing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: